Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and "Off" Episodes
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, efficacy and pharmacokinetics following
administration of CVT-301 in treatment of "off" episodes in Parkinson's Disease patients.
Phase:
Phase 2
Details
Lead Sponsor:
Acorda Therapeutics
Collaborator:
Michael J. Fox Foundation for Parkinson's Research
Treatments:
Carbidopa Carbidopa, levodopa drug combination Levodopa